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ABSTRACT 
The human vagina is a dynamic ecosystem in which homeostasis depends on mutually 
beneficial interactions between the host and their microorganisms. However, the vaginal 
ecosystem can be thrown off balance by a wide variety of factors. Bacterial vaginosis 
(BV) is the most common vaginal infection in women of childbearing age, but its 
etiology is not yet fully understood, with different controversial theories being raised 
over the years. What is generally accepted is that BV is often characterized by a shift in 
the composition of the normal vaginal microbiota, from a Lactobacillus species 
dominated microbiota to a mixture of anaerobic and facultative anaerobic bacteria. 
During BV, a polymicrobial biofilm develops in the vaginal microenvironment, being 
mainly composed of Gardnerella species. The interactions between vaginal 
microorganisms are thought to play a pivotal role in the shift from health to disease and 
might also increase the risk of sexually transmitted infections acquisition. Here we 
review the current knowledge regarding the specific interactions that occur in the 
vaginal niche and discuss mechanisms by which these interactions might be mediated. 
Furthermore, we discuss the importance of novel strategies to fight chronic vaginal 
infections. 
INTRODUCTION 
The female vaginal environment is a complex and dynamic nutrient-rich milieu for 
microorganisms, resulting in a unique microbiome (Lloyd-Price, Abu-Ali and 
Huttenhower 2016). Apart from being a passage for the menstrual flow, sperm and the 
baby, the human vagina and its microbiota have an impact on conception, pregnancy, 
the mode and timing of the baby delivery and the risk of acquisition sexually 
transmitted infections (STIs) (Amabebe and Anumba 2018a). 
The healthy vaginal mucosa of reproductive-aged women consists of a stratified 
squamous non-keratinized epithelium of about 28 cell layers covered by a mucosal 
stratum constantly lubricated by cervicovaginal fluid (Patton et al. 2000). The apical 
layers of the vaginal epithelium are comprised of dead cornified cells that are 
uninfectable, serving thus, as a shield against pathogens (Anderson, Marathe and 
Pudney 2014). Still, these protective layers are constantly being challenged and 
eventually can be disrupted, enabling the invasion of pathogens and the development of 
infections (Cone 2014). Most of the time, these infections are governed by diverse 
interactions among existing pathogens in the vaginal environment, such as the case of 
bacterial vaginosis (BV). In this review, we will briefly discuss some of the underlying 
aspects shaping the communities that have a key impact on the development of BV. The 
relation between this condition and other vaginal infections (or unbalances of the 
vaginal microbiota) will also be addressed as well as its association with sexual 
intercourse. Lastly, the focus will be on the limitations of the current antibiotic 
treatment and the importance of finding and developing novel strategies to effectively 
treat BV and other vaginal infections. 
THE VAGINAL MICROBIOTA IN HEALTH 
Since the first microbiological study of the human vagina published in 1892 by Albert 
Döderlein, the vaginal microbiota of healthy reproductive women has been described as 
principally containing Gram-positive bacilli of the genus Lactobacillus (Döderlein 
1892). Generally, vaginal colonization with lactobacilli is believed to promote a 
protective environment since these bacteria prevent other microbes from colonizing the 
vaginal tract, using several mechanisms (Vaneechoutte 2017; Kovachev 2018).  
One of the best defense mechanisms studied is related to the production of lactic acid by 
the majority of Lactobacillus spp., which contributes to the maintenance of the vaginal 
pH below 4.5 (Tachedjian et al. 2017; Godha et al. 2018). This acidic environment 
represents an efficient mechanism of protection of the vaginal milieu since it makes the 
environment unwelcoming to many other bacteria while favoring the presence of 
lactobacilli (O’Hanlon, Moench and Cone 2013; Prabhurajeshwar and Chandrakanth 
2017). In addition to lactic acid, Lactobacillus spp. are also known to produce broad-
spectrum bacteriocins which might play an important role in fending off non-indigenous 
bacteria or pathogenic microorganisms (Dover et al. 2008; Stoyancheva et al. 2014) 
through permeabilization of their membrane (Oscáriz and Pisabarro 2001). Furthermore, 
lactobacilli produce hydrogen peroxide that could act as a natural microbicide within the 
vaginal ecosystem (Atassi and Servin 2010; Sgibnev and Kremleva 2015). However, it 
has been described that physiological concentrations of this metabolite produced no 
detectable inactivation of BV-associated bacteria when these were incubated under 
optimal, anaerobic growth conditions (O’Hanlon, Moench and Cone 2011). Therefore, 
hydrogen peroxide role in the vaginal environment is still being debated (Tachedjian, 
O’Hanlon and Ravel 2018). Lactobacillus spp. are also able to interfere with the 
adhesion of pathogenic bacteria to the vaginal epithelium, as has been shown in several 
in vitro studies (Castro et al. 2013, 2015; Leccese Terraf et al. 2017). This ability of 
lactobacilli has an important role since the pathogen adhesion and colonization on the 
host cells often represent the first step of the infection process (Ribet and Cossart 2015). 
Besides Lactobacillus spp., the vaginal microbiota of asymptomatic women of 
reproductive age also harbors other distinct taxa (Drell et al. 2013). Based on the 
differences in the composition and abundance of vaginal bacterial species, the vaginal 
microbiota of childbearing-age women has been devised in five major types, known as 
community state types (CST). Four of these CST are dominated by Lactobacillus 
crispatus (CST I), Lactobacillus gasseri (CST II), Lactobacillus iners (CST III), and 
Lactobacillus jensenii (CST V), while the CST IV does not contain a significant number 
of lactobacilli, but is composed of a varied array of facultative and strictly anaerobic 
bacteria, including Gardnerella, Atopobium, Prevotella, Mobiluncus, Sneathia, 
Eggerthella, Finegoldia, Megasphaera, Peptoniphilus, Corynebacterium, 
Streptococcus, and Aerococcus (Ravel et al. 2011; Drell et al. 2013). The proportion of 
each CST varies among the four ethnic groups (Asian, white, black, and Hispanic), as 
described in Figure 1. Interestingly, these variations among CST appear to be driven by 
a combination of genetic, behavioral, cultural, and other uncharacterized underlying 
factors (Ma, Forney and Ravel 2012; Borgdorff et al. 2017). However, all CST contain 
members that have been assigned to genera known to produce lactic acid, such as 
Lactobacillus, Atopobium, Megasphaera, and Streptococcus, being suggested that this 
ability may be conserved among communities (Ravel et al. 2011). Overall, these 
findings challenged the wisdom that the occurrence of high numbers of lactobacilli is 
synonymous with “normal and healthy” since approximately 30% of healthy women 
lack considerable numbers of Lactobacillus spp. (Forney, Foster and Ledger 2006; 
Ravel et al. 2011; Gajer et al. 2012). 
In addition to the protective effects of the beneficial endogenous vaginal microbiota, the 
colonization of pathogenic microorganisms in the female reproductive tract is prevented 
by local components of the immune system (Hickey et al. 2011; Nguyen et al. 2014). 
The innate immune system represents the first line of response to infection and, for this 
reason, has a pivotal role in the host (Amjadi et al. 2014). In the female reproductive 
tract, the innate immune system consists of several components that provide specific 
protective barriers against the invasion of pathogens (Farage et al. 2011). The lining 
mucosa, made up of epithelial cells and mucus, acts as a physical barrier (Tjabringa et 
al. 2005; Hickey et al. 2011). Mucus is composed of glycoproteins, known as mucins, 
which trap pathogens in a thick gel phase, preventing their ascending in the upper 
female reproductive tract (Taherali, Varum and Basit 2018). Contrariwise, pattern 
recognition receptors, especially Toll-like receptors (Fazeli, Bruce and Anumba 2005; 
Kumar, Kawai and Akira 2011) and natural antimicrobial peptides (Yarbrough, Winkle 
and Herbst-Kralovetz 2015) form a chemical barrier. Toll-like receptors recognize 
conserved pathogen-associated molecular patterns synthesized by various 
microorganisms, being thought that the expression of Toll-like receptors by the 
epithelium plays an important role in antigen detection and initiation of the immune 
response (Nasu and Narahara 2010). On the other hand, antimicrobial peptides, small 
molecules normally with less than 50 amino acids, which are mostly represented by 
defensin (Yarbrough, Winkle and Herbst-Kralovetz 2015), elafin (Wira et al. 2011), 
cathelicidin (Doss et al. 2010), lysozyme (Wira et al. 2011), secretory leukocyte 
protease inhibitor (Orfanelli et al. 2014), and lactoferrin (Valenti et al. 2018), are 
produced in the vaginal environment (Zhang and Gallo 2016) and have broad-spectrum 
antibacterial activity. Moreover, these substances play additional biological functions 
including cell proliferation, cytokine induction, chemotaxis, and modulation of innate 
and adaptive immunity (Amjadi et al. 2014). Overall, the beneficial endogenous vaginal 
microbiota together with the immune system provides protection in the vaginal 
environment whose state has a significant impact on the health of women, their partners, 
as well as their newborns (Li et al. 2012). Alterations in the composition of the vaginal 
microbiota have been linked to several adverse health outcomes, as discussed in the next 
section. 
UNBALANCED VAGINAL MICROBIOTA IN DISEASE 
The vaginal microbiota has been indicated to be a temporal dynamic ecosystem subject 
to changes over the menstrual cycle (Gajer et al. 2012; Nugeyre et al. 2019). Moreover, 
microbial communities present in the vagina may undergo different types of acute and 
chronic disturbances caused by endogenous and exogenous factors including phase of 
the menstrual cycle (Lopes et al. 2011), aging (Uchihashi et al. 2015), stress (Amabebe 
and Anumba 2018b), hormonal contraceptives (Fosch et al. 2018), pregnancy (Romero 
et al. 2014), use of antibiotics (Macklaim et al. 2015), vaginal douching (Luong et al. 
2010), vaginal lubricants (Marrazzo et al. 2010a), and sexual activity (Vodstrcil et al. 
2017). These alterations can cause periods of increased host susceptibility that 
negatively impact the ability of the vaginal community to resist pathogen colonization 
(Huang et al. 2014), leading thus to microbial unbalances in the urogenital tract, that 
can lead to infection and disease development (Donders et al. 2000). The most common 
vaginal infections are caused by bacteria (such as vaginal bacteriosis, commonly known 
as BV, or aerobic vaginitis), by fungus (vulvovaginal candidiasis) and by protozoa 
(trichomoniasis) as listed in Table 1 and represented in Figure 2. It is also important to 
note that some STIs can also influence the vaginal microbiota (van de Wijgert 2017). 
Table 2 briefly lists associations between BV and the most common vaginal infections 
or STIs. 
Bacterial vaginosis (BV) 
Worldwide, BV is the most common gynecological infection among women of 
childbearing age, affecting approximately 30% of women in the general population and 
50% of African American women (Kenyon, Colebunders and Crucitti 2013). 
Microbiologically, BV is characterized by a dramatic shift in the vaginal microbiota 
from the dominant lactic acid and hydrogen peroxide-producing lactobacilli to a 
polymicrobial microbiota, consisting of strictly and facultative anaerobic bacteria, 
where Gardnerella vaginalis plays a pivotal role (Onderdonk, Delaney and Fichorova 
2016). It is worth noting that an emended description of G. vaginalis was recently 
proposed with delineation of 13 genomic species within the genus Gardnerella 
(Vaneechoutte et al. 2019). As such, in this review, we will use the term Gardnerella 
spp. when discussing previous publications. 
In the last years, BV has emerged as a global issue of concern due to its association with 
a wide array of adverse outcomes. It has been reported that BV significantly increases 
the risk of development of gynecological postoperative infections (Lin et al. 1999), 
pelvic inflammatory disease (Ness et al. 2005), urinary tract infections (UTIs) 
(Harmanli et al. 2000) and infertility (Salah et al. 2013). Moreover, BV has been also 
associated with adverse pregnancy outcomes such as miscarriage and recurrent 
pregnancy losses (Isik et al. 2016), preterm delivery and low birth weight (Svare et al. 
2006) and increased neonatal morbidity (Dingens et al. 2016). Furthermore, BV 
facilitates the transmission of STIs agents including the human immunodeficiency virus 
(Haddad et al. 2018), human papillomavirus (Gillet et al. 2011), Neisseria gonorrhoeae 
and Chlamydia trachomatis (Wiesenfeld et al. 2003). 
Is BV a disease? 
Despite advances in our understanding of BV, there are still a lot of controversies. BV 
has been described as a disease (Eschenbach 1993), a condition (Holzman et al. 2001), a 
vaginal inflammation (Forsum et al. 2005), a disorder (Patterson et al. 2010), a clinical 
syndrome (Workowski and Bolan 2015), a dysbiosis or microbial imbalance (Muzny 
and Schwebke 2016), an infection (Bagnall and Rizzolo 2017), and in some women, a 
normal situation in which women do not present any symptoms (Gibbs 2007). It should 
be noted that while the term condition can be applied to an unspecific state of health, 
whether well or ill, when it is conferring illness, a condition can further be classified as 
a disease or a disorder (Merchant et al. 2019). It has been proposed that in order to fit 
the definition of a disease, it is required the appearance of precise signs and symptoms 
(Scully 2004; Tikkinen et al. 2012). On the other hand, a disorder denotes an 
abnormality of regular functions in the body or part of the body and could be a result of 
the disease or even lead to the development of other diseases (Cooper 2004). 
Conversely, the concept of infection is traditionally used to describe when a 
microorganism that causes disease enters the host and begins to multiply (World Health 
Organization Regional Office for Europe 2001). However, it should not be neglected 
that some infections can be asymptomatic, never leading to disease development, such 
as what can occur during hepatitis B (Liang 2009) or cytomegalovirus infection 
(Caliendo et al. 2002). Indeed, a similar situation also occurs in BV, since 
approximately half of the women who experience BV are asymptomatic (Eschenbach et 
al. 1988; Gibbs 2007; Turovskiy et al. 2011). It is, therefore, reasonable to assume that 
asymptomatic women colonized by Gardnerella might be suffering an infection, but not 
suffering a disease, as represented in Figure 3. The infection could occur early in 
women’s life and remain asymptomatic (Catlin 1992; Centers for Disease Control and 
Prevention 2016). In fact, a similar situation occurs with many opportunistic pathogens, 
such as with Staphylococcus epidermidis (Le, Park and Otto 2018). In cases of 
symptomatic BV infection, there is a presence of clinical symptoms as further discussed 
below, in the section Clinical features and diagnosis of BV. It should be noted that the 
recent acknowledgement of the existence of up to 13 different Gardnerella species 
(Vaneechoutte et al. 2019) might explain some of the controversial studies to date. It is 
not known, so far, if different species are more associated with asymptomatic 
colonization or more prone to develop symptomatic infection leading to disease (Hill et 
al. 2019; Khan, Voordouw and Hill 2019).  
Another point of controversy is related to the inflammatory response associated with 
BV. Often BV is not inflammatory (Weissenbacher et al. 2010; Danielsson, Teigen and 
Moi 2011) but in some cases it has been reported an association of BV with cervicitis 
(Schwebke and Weiss 2002) with increased inflammatory markers (Sturm-Ramirez et 
al. 2000). Furthermore, recent reviews of studies on cytokines, chemokines, 
antimicrobial factors, and cellular immune parameters indicated that inflammation may 
occur in some BV patients (Mitchell and Marrazzo 2014; Borgdorff et al. 2016). It was 
therefore suggested that the differences in the inflammatory response among women 
with BV could either be associated with microbial and host diversity or could be the 
result of differences in the study design (Mitchell and Marrazzo 2014).  
Some authors now question that what is commonly called BV might, in fact, be 
different clinical conditions (Cerca et al. 2017; Reid 2018, 2019). If true, this would 
explain many of the controversial studies. In this regard, Reid proposed that the term of 
BV should be dropped, as it currently offers no adequate description of a single 
condition, suggesting two potential terms: vaginal dysbiosis and vaginal inflammation 
(Reid 2018). In any case, to avoid underdiagnosis or misdiagnosis of vaginal infections, 
each situation should be properly examined by evaluating the presence and abundance 
of specific bacteria as well as the clinical signs and symptoms (Schwiertz et al. 2006).  
Clinical features and diagnosis of BV 
In symptomatic women, BV is characterized by the presence of a profuse vaginal 
discharge and fishy vaginal odor (Frobenius and Bogdan 2015). The abnormal vaginal 
discharge results in part from the degradation of the protective vaginal mucin gel, which 
is performed by mucin-degrading enzymes produced by BV-associated bacteria 
(Olmsted et al. 2003). The fishy odor is due to the volatilization of amines produced as 
a result of the metabolism of anaerobic bacteria (Wolrath et al. 2001). In clinical 
settings, BV is commonly diagnosed using the Amsel criteria, which include the 
presence of at least three of the following precepts: (i) thin and homogenous discharge, 
(ii) vaginal pH over 4.5, (iii) positive “whiff test” (detection of fishy odor through the 
addition of 10% potassium hydroxide to vaginal fluid) and (iv) presence of clue cells on 
microscopic examination of vaginal fluid (Amsel et al. 1983). However, these clinical 
signs are not always present, making Amsel criteria somewhat subjective (Sha et al. 
2005). 
In an attempt to improve the accuracy in BV diagnosis, Nugent and colleagues proposed 
a Gram stain scoring system for examining vaginal smears (Nugent, Krohn and Hillier 
1991). This method derived from the modification of the Gram-stained protocol 
proposed by Spiegel and colleagues (Spiegel, Amsel and Holmes 1983) and currently it 
is regarded as the gold standard for BV diagnosis (Sha et al. 2005). According to the 
Nugent criteria, Gram-stained smears are used for identification, classification, and 
quantification of the following bacterial morphotypes: large Gram-positive bacilli 
(Lactobacillus spp.), small Gram-variable rods (Gardnerella spp. and Bacteroides spp.), 
and curved Gram-variable rods (Mobiluncus spp.), as summarized in Table 3. Each 
morphotype is scored in a scale from 0 to 4+, regarding the number of morphotypes 
observed per oil immersion field. Thus, a score of 0–3 is considered normal vaginal 
microbiota, 4–6 as intermediate microbiota and 7–10 as BV (Figure 4). Nevertheless, 
Nugent score has some disadvantages, especially related to the inter-observer variability 
and it requires skilled personnel to perform it. Importantly, the relationship between 
Gram stain score and diagnosis by the clinical criteria is imperfect. Gram stain is more 
sensitive, whereas the Amsel criteria can be more specific. Overall, the concordance 
between them is of 80% to 90% (Livengood 2009). These shortcomings of standard 
methods make BV diagnosis a challenging task, and, therefore, alternative methods for 
BV diagnosis have been investigated. The molecular methodologies, such as 
polymerase chain reaction (PCR) (Fredricks et al. 2007), quantitative PCR (qPCR) 
(Hilbert et al. 2016) or fluorescence in situ hybridization (Machado et al. 2015), have 
allowed the detection or even quantification of the main BV-associated bacteria. In fact, 
they have improved our knowledge of how microbial species interact among themselves 
and with the human host. However, most of these alternative methods are expensive and 
many of them still require validation (Africa 2013). A recent review of molecular 
methods for BV diagnosis discusses in detail how the field has evolved and current 
shortcomings. Despite the wide variety of diagnostic assays available to diagnose BV, 
the authors concluded that clinicians will need to consider costs, result time, and 
accuracy in their decision to select a particular assay to test for BV (Coleman and 
Gaydos 2018). 
Treatment of BV 
The Centers for Disease Control and Prevention and the International Union against 
Sexual Transmitted Infections recommend that all symptomatic women should be 
treated, since they recognize numerous benefits of therapy including the relief of the 
symptoms and signs of infection and reduction in the risk of STIs and BV-associated 
complications, mainly in pregnancy (Sherrard et al. 2011; Workowski and Bolan 2015). 
However, there is insufficient evidence to recommend routine treatment of 
asymptomatic women (Schwebke 2000; Gibbs 2007; Nygren et al. 2008). 
Conventionally, BV is treated with either metronidazole, clindamycin or tinidazole 
(Workowski and Bolan 2015). Despite some studies reported short-term high clinical 
cure rates of antibiotic therapy (Paavonen et al. 2000; Thulkar, Kriplani and Agarwal 
2012), high recurrence levels have been demonstrated within 3–12 months (Bradshaw et 
al. 2006a; Bilardi et al. 2016). Therefore, treatment of recurrent BV can be difficult and 
may require extended courses of antibiotic therapy to obtain a long-lasting cure (Bagnall 
and Rizzolo 2017). 
Currently, metronidazole, the most widely known of nitroimidazole drug class, 
represents the first line therapy for BV and also for trichomoniasis (Sobel and Sobel 
2015). However, several side effects are associated with metronidazole therapy, such as 
nausea, vomiting and gastrointestinal complaints (Miljkovic et al. 2014; Sobel and 
Sobel 2015). Clindamycin is the second recommended antimicrobial agent for the 
treatment of BV, with similar efficacy as metronidazole (Paavonen et al. 2000; Menard 
2011). This lincosamide antibiotic has various formulations including vaginal dosage 
forms (ovules and cream) and oral (systemic) pills (Menard 2011). Importantly, topical 
clindamycin tented to cause a lower rate of adverse side effects (metallic taste in the 
mouth, nausea, vomiting) than oral metronidazole. Nonetheless, the administration of 
clindamycin seems to be a risk factor for the development of Clostridium difficile 
infection (Mullish and Williams 2018). Furthermore, because both clindamycin ovules 
and cream are oil-based, their use might interfere with the safety of latex condoms and 
diaphragms (Workowski and Bolan 2015). Finally, tinidazole is currently considered an 
alternative antimicrobial agent for BV treatment, particularly whenever metronidazole 
and clindamycin are not tolerated (Workowski and Bolan 2015). Being a second-
generation nitroimidazole, tinidazole requires lower dosages and is administered less 
frequently than metronidazole due to its longer half-life (Wood and Monro 1975). The 
increasing evidence that BV is a recurrent infection (Wilson 2004) sparked the interest 
of the scientific community in exploring emerging therapeutic alternatives (Machado et 
al. 2016), which will be also addressed in the section Importance of novel strategies to 
fight chronic vaginal infections on this review. 
Etiology of BV 
BV etiology is a matter of controversy. It is still not clear if the shift from healthy to BV 
microbiota could occur because BV pathogens overgrowth and outcompete the resident 
lactobacilli or if the initial loss of lactobacilli is the trigger for subsequent BV pathogens 
colonization (Martin 2012; Onderdonk, Delaney and Fichorova 2016). In vitro, it was 
previously shown that BV-associated Gardnerella spp. is able to displace pre-adhered 
L. crispatus and initiate vaginal colonization (Castro et al. 2015). Conversely, the 
hypothesis of the depletion of lactobacilli as the cause of BV has not been fully 
supported by the fact that some women maintain a “healthy” vaginal environment 
without lactobacilli (Jung et al. 2017). Curiously, as also mentioned above, some strains 
of Atopobium spp., Leptotrichia spp., and Megasphaera spp. are reportedly capable of 
producing lactic acid. Therefore, the presence of non-lactobacilli vaginal microbiota and 
the lack of beneficial lactobacilli may not necessarily be sufficient to cause BV (Zhou et 
al. 2004; Gajer et al. 2012). 
As such, the lack of basic information about etiopathogenesis of BV led to the 
postulation of two main hypotheses. The first is the primary pathogen hypothesis, which 
infers that a single pathogenic species, Gardnerella spp., is the etiological agent of BV, 
usually transmitted by sexual contact (Muzny and Schwebke 2013). In contrast, the 
second is the polymicrobial hypothesis, which argues that Gardnerella spp. acts in 
concert with other bacteria, principally anaerobes, to cause BV (Josey and Schwebke 
2008). 
Historically, in 1955, Gardner and Dukes identified what they called Haemophilus 
vaginalis (first classification attributed to G. vaginalis) as the etiological agent of BV, 
as they claimed H. vaginalis fulfilled all the Koch’s postulates (Koch 1876), as 
summarized in Table 4. However, a later study pointed out some failures in these 
experiments since they showed that the artificial infection with a pure culture of H. 
vaginalis did not always cause BV (Criswell et al. 1969). The assumption was then 
made that H. vaginalis was not the specific causative agent of BV, failing one of Koch’s 
postulates. Afterwards, it was found that several other anaerobic bacteria were presented 
during BV episodes (Spiegel et al. 1983; Holst et al. 1984; Hill 1993), and this led to 
the postulation of the polymicrobial etiology hypothesis (Josey and Schwebke 2008). 
This hypothesis was supported by the demonstrations that anaerobic activity is 
instrumental in producing the symptoms of BV, namely the vaginal odor, as a result of 
the production of amines as a byproduct of anaerobic metabolism (Chen et al. 1979; 
Wolrath et al. 2001). However, the presence of any specific bacterium in BV has been 
rarely supported by microbiological functional studies, demonstrating, thus, a lack of 
virulence profile characterization of such species (Machado and Cerca 2015). 
Notwithstanding all these findings, the polymicrobial hypothesis is still incongruent 
with the epidemiological profile of BV since multiple studies have been revealing that 
BV reflects the behavior of a sexually transmitted or enhanced disease (Fethers et al. 
2008; Verstraelen et al. 2010; Leppäluoto 2011). 
Bacterial species involved in BV 
Even though the current knowledge about BV etiology remains scarce, the common 
consensus is that BV is always associated with the overgrowth of numerous bacterial 
species, including Gardnerella spp., Atopobium vaginae, Fusobacterium nucleatum, 
Mobiluncus mulieris, Mycoplasma hominis, Prevotella bivia, and Ureaplasma 
urealyticum (Livengood 2009). With the advance in culture-independent methods, the 
spectrum of anaerobes detected in women with BV was greatly expanded with the 
addition of Bifidobacterium, Dialister, Eggerthella, Leptotrichia, Megasphaera, and 
Slackia organisms, as well as other bacteria related to Arthrobacter, Caulobacter, and 
Butyrivibrio organisms (Romero et al. 2014; Muzny et al. 2018). Furthermore, the 
Vaginal Human Microbiome Project has detected several newly described bacteria in 
the Clostridiales order, which were initially designated BV-associated bacteria 
(BVAB): BVAB1, BVAB2, or BVAB3 (Fredricks, Fiedler and Marrazzo 2005; Huang 
et al. 2014). To date, only BVAB3 has been cultured and biochemically characterized 
and the remaining two BVAB (BVAB1, BVAB2) have not yet been isolated by culture 
(Austin et al. 2015). The species name of BVAB3 was proposed as Mageeibacillus 
indolicus (Austin et al. 2015). Interestingly, differences in the BV vaginal microbiota 
between American women and women of European ancestry were found, with 
American women more likely to be colonized by Anaerococcus tetradius, BVAB1, 
BVAB3, Coriobacteriaceae, Sneathia, Parvimonas, Dialister, Megasphaera, Bulleidia, 
Prevotella, and Atopobium species, while women of European ancestry were more 
likely to be colonized by M. hominis, Dialister micraerophilus, and Gemella species 
(Huang et al. 2014). 
A particular species that is often found in BV is L. iners (Wertz et al. 2008; Shipitsyna 
et al. 2013), being thus evident that not all vaginal Lactobacillus spp. are necessarily 
beneficial and protective. Indeed, L. iners is very different from other lactobacilli, not 
producing D-lactic acid (Mendes-Soares et al. 2014; Edwards et al. 2019) and carrying 
some pathogenicity factors, such as inerolysin, a cytotoxin that was found to be up-
regulated at least six-fold in women presenting BV (Macklaim et al. 2011, 2013). 
Interestingly, it has been suggested that L. iners is a dominant part of the vaginal 
microbiota in a transitional stage between BV and normal microbiota (Ferris et al. 2007; 
Jakobsson and Forsum 2007). Nevertheless, to date, the role that L. iners plays in the 
vaginal microenvironment still remains controversial and further investigations are 
needed to clarify this matter. 
Unfortunately, despite the development of a more comprehensive picture of the vaginal 
microbiota during BV through the use of high-throughput 16S rRNA sequencing, the 
significance of these findings remains unclear, since it is not known whether these 
microorganisms are pathogens that cause BV or if they simply are opportunistic 
microorganisms that take advantage of the temporary higher pH environment and thus 
increase in numerical dominance (Ma, Forney and Ravel 2012). 
THE EPIDEMIOLOGY OF BV IN RELATION TO SEXUAL BEHAVIOR – IS BV A STI? 
As discussed above, there is strong evidence that BV is associated with the acquisition 
of other infections, including STIs. It has also been suggested that BV might be sexually 
transmitted (Muzny and Schwebke 2016) and thus, in this regard, several 
epidemiological studies have described many sexual risk factors that may enhance its 
acquisition. According to these studies, women are more probable to have BV if they: 
(i) report a high number of lifetime sexual partners (Fethers et al. 2008), (ii) have a new 
sexual partner (Schwebke and Desmond 2005), (iii) were at young age on coitarche 
(Verstraelen et al. 2010), (iv) use oral contraception instead of condom (Silva et al. 
2013), (v) identify themselves as commercial sex workers (Schwebke 2005), or (vi) 
have high frequency of intercourse (Vallor et al. 2001). In addition, there are several 
studies regarding women who have sex with women that also support the sexual 
transmission of BV (Bradshaw et al. 2014; Vodstrcil et al. 2015; Muzny et al. 2019a). 
Moreover, males as asymptomatic carriers possibly could be also considered being 
responsible for the transmission of BV, since their preputial space and distal urethra is 
suspected to act as a reservoir of BV-associated bacteria, which might be transferred to 
the female partners through sexual contact and where these may act as BV-inducing 
microorganisms (Swidsinski et al. 2010; Liu et al. 2015; Zozaya et al. 2016).  
Despite the fact that BV may present a close relationship with sexual behavior, there is 
also some criticism and controversial studies (Morris, Rogers and Kinghorn 2001; 
Fethers et al. 2008). Of note, Gardnerella has also been isolated from adolescent 
women with no sexual activity (Bump and Buesching 1988) and recurrent BV has also 
been reported in a virgin adolescent (Papanikolaou et al. 2002). It is noteworthy, that in 
both studies the virginal status of the adolescents was carefully examined by a physician 
reveling an intact hymen on the vagina. Hence, an alternative infectious disease model 
emerged, in which BV was described as a sexually enhanced disease rather than a 
sexually transmitted infection, as summarized in Figure 5. Verstraelen and colleagues 
proposed two mechanisms that could support this alternative model (Verstraelen et al. 
2010). Thus, it was thought that unprotected sexual intercourse is associated with an 
alteration of the physicochemical vaginal environment, affecting also the vaginal 
microbiota. The alkaline prostatic content of the ejaculate raises the vaginal pH and 
makes the environment less favorable to the survival of lactobacilli (Boskey et al. 
1999), promoting at the same time the growth of BV-associated microorganisms (Hay 
2005). As such, condom utilization would protect against BV development by hamper 
acidification of the vaginal environment and not by preventing transmission of an 
infectious agent. However, this has not been demonstrated yet. They also suggested that 
both protected and unprotected vaginal penetration could, in some way, promote the 
transfer of perianal, perineal, and perivulvar bacteria to the vagina, inducing BV 
(Verstraelen et al. 2010). Additionally, non-coital sexual behaviors, including receptive 
oral (Marrazzo et al. 2010b) and anal sex (Cherpes et al. 2008) and non-penetrative 
digito-genital contact (Fethers et al. 2009), might alter the vaginal microbiota 
equilibrium through the transfer of BV-associated bacteria from the rectal and perineal 
regions to the vulvar region and the vagina, possibly also enhancing BV development. 
In addition, it is noteworthy that women with BV alone or with concurrent Candida spp. 
infections present a high risk of coinfection with STIs, as has been shown in a recent 
study developed by Van Der Pol and colleagues (Van Der Pol et al. 2019). Overall, the 
BV epidemiology in relation to sexual behavior still remains controversial and it is not 
surprising that BV has been referred to as "one of the most prevalent enigmas in the 
field of medicine" (Schwebke 1997; Larsson et al. 2005; Marrazzo 2011). Although BV 
presents high clinical importance, the exact global prevalence is unknown since it varies 
according to the characteristics of the studied population (Kenyon, Colebunders and 
Crucitti 2013). 
POLYMICROBIAL NATURE OF VAGINAL BIOFILMS IN BV 
A shift in the paradigm of BV research occurred in 2005 when Swidsinski and 
colleagues revealed the presence of a polymicrobial biofilm adhering to the vaginal 
epithelial cells in BV, using fluorescence in situ hybridization (Swidsinski et al. 2005). 
This biofilm was shown to contain high concentrations of a variety of bacterial groups, 
being Gardnerella spp. the most predominant member. Several other studies validated 
these findings and it is currently accepted that BV-related biofilms are strongly 
associated with Gardnerella spp. (Swidsinski et al. 2013, 2014, 2015; Hardy et al. 
2015; Machado et al. 2015). 
Biofilms can be defined as structured communities of bacteria embedded in a self-
produced matrix of extracellular polymeric substances (Flemming et al. 2016). These 
complex structures often contain channels which allow circulation of nutrients. Also, 
they may contain genetically identical cells in separate regions of the biofilm that 
exhibit different patterns of gene expression (López, Vlamakis and Kolter 2010). This 
results in certain advantages to the biofilm community, including an enhanced tolerance 
and a better persistence toward adverse environmental stress conditions (Castro et al. 
2017; Romero-Lastra et al. 2017; Kot, Sytykiewicz and Sprawka 2018). The formation 
of the biofilm is a dynamic and complex process that involves multiple interactions 
between single or multiple bacterial species and the host cells (Kriebel et al. 2018). Its 
life cycle generally includes several stages: (i) adhesion to a substrate, (ii) production of 
extracellular polymeric substances with the development of a mature biofilm structure 
and (iii) dispersal by the detachment of aggregates or by the release of single cells 
(Machado and Cerca 2015). 
To date, the exact process of the development of a biofilm in BV remains unknown 
(Hardy et al. 2017; Jung et al. 2017). However, there is evidence supporting that the 
first stage of biofilm formation, corresponding to microbial adhesion to vaginal 
epithelial cells, is an essential factor to elicit BV (Swidsinski et al. 2005). This process 
minimizes the contact of microbes with potentially deleterious extracellular enzymes 
and antibodies as well as reduces their chances of being flushed away in vaginal fluid or 
urine (Verstraelen and Swidsinski 2013; Salo et al. 2016). Notable is the fact that the 
ability of Gardnerella spp. to colonize vaginal cells was already recognized in the 
eighties (Johnson and Boustouller 1987; Scott, Curran and Smyth 1989). Indeed, 
vaginal epithelial cells covered with bacteria, the so-called clue-cells, which represent 
one of the Amsel criteria used to diagnose BV, are exactly what one expects to see in 
the case of biofilm formation. Interestingly, clue cells were recognized for decades 
(Amsel et al. 1983; Cook et al. 1989; Nelson and Macones 2002), but only recently they 
were associated to the biofilm formation process (Swidsinski et al. 2005). 
More recently, Machado and colleagues demonstrated that Gardnerella spp. was able to 
adhere to epithelial cells and displace pre-coated L. crispatus, while other BV-
associated species, including A. vaginae, M. mulieris, F. nucleatum, and P. bivia were 
outcompeted by the protective lactobacilli (Machado et al. 2013). A subsequent study 
confirmed that Gardnerella spp. has a higher virulence potential and ability to adhere to 
epithelial cells than 29 other BV-associated bacteria (Alves et al. 2014). Still an enigma 
is whether Gardnerella spp. alone is able to trigger BV or whether Gardnerella spp. has 
to interact with other bacteria to cause BV. This will be discussed in the next section. 
Interactions within vaginal microbes 
The importance of interspecies interactions within biofilm communities has been 
described for bacteria present in the oral cavity (Kolenbrander et al. 2010; Kriebel et al. 
2018), gastrointestinal tract (von Rosenvinge et al. 2013), lung environment (Boisvert et 
al. 2016), as well as in the vaginal environment (Hardy et al. 2017). Interactions among 
species can be either synergistic, which are able to exert their effect by modifying the 
environment, so it becomes appropriate for neighboring species or by producing 
specific metabolites which stimulate the growth of other organisms (Pybus and 
Onderdonk 1999), or antagonistic (Moons, Michiels and Aertsen 2009). The last can 
result in competition over nutrients and growth inhibition. Regarding the interactions 
that occur between the microbial members within vaginal biofilms communities, our 
understanding is still in its infancy (Hardy et al. 2017). However, such interactions 
might have a significant impact on the vaginal environment, influencing the success of 
antimicrobial therapy. Similar to what occurs in the oral cavity, it has now been 
hypothesized that Gardnerella spp. is the initial colonizer that enables other BV-related 
bacteria to subsequently adhere and incorporate the early biofilm (Verstraelen and 
Swidsinski 2013; Muzny et al. 2019b), as depicted in Figure 6.  
Interactions between Gardnerella spp., BV-associated pathogens and commensal bacteria 
Recognizing BV as a polymicrobial condition, several studies have suggested that 
interactions between BV-associated species may contribute to its progression and 
pathogenesis, as summarized in Table 5. Accordingly, our research group has started to 
investigate bacterial interactions within dual-species biofilms following the hypothesis 
that Gardnerella spp. is the early colonizer during BV. Using an in vitro model that 
allows a Gardnerella spp. biofilm to develop and then introduces a second species, our 
group demonstrated that some of the BV-associated species had the ability to establish 
synergistic interactions and augment Gardnerella spp. pre-formed biofilm, while others 
presented antagonistic activity (Castro and Cerca 2015). By performing confocal laser 
scanning microscopy, we observed that the biofilm structures among bacterial consortia 
differentiate in at least three unique dual-species biofilm morphotypes (Castro, 
Machado and Cerca 2019). Interestingly, the impact of the second BV-associated 
species in Gardnerella spp. virulence, as assessed by the quantification of key genes, 
such as the genes encoding for vaginolysin or sialidase, varied significantly, suggesting 
that some, but not all species, could be contributing to enhanced symptoms associated 
with BV (Castro, Machado and Cerca 2019). 
Among synergistic interactions reported in BV, a few studies have identified specific 
nutritional pathways involving BV-associated bacteria. An early in vitro study reported 
nutritional pathways to upkeep the synergistic relationship observed between 
Gardnerella spp. and P. bivia. Growth of P. bivia in a vaginal defined medium 
supplemented with amino acids or peptone resulted in ammonia production while the 
growth of Gardnerella spp. under the same conditions was accompanied by ammonia 
utilization (Chen et al. 1979). Consequently, ammonia flow from P. bivia to 
Gardnerella spp. was proposed as a mechanism to support this commensal interaction 
(Pybus and Onderdonk 1997). Additionally, more evidence of such bacterial 
cooperation was supported by a study from our research group, where we demonstrated 
that Gardnerella spp. growth increased in the presence of P. bivia, and P. bivia reached 
higher numbers when co-cultured with Gardnerella spp. (Machado, Jefferson and Cerca 
2013). Besides these findings, a more recent study showed, in a mice model, that the 
presence of Gardnerella spp. enhanced the invasive potential of P. bivia, facilitating its 
ascension into the uterus (Gilbert et al. 2019). 
Another early study reported an enhancement of Peptostreptococcus anaerobius growth 
in the presence of P. bivia, but not in pure culture (Pybus and Onderdonk 1998). After 
analyzing P. bivia culture supernatants, these authors found an increased concentration 
of amino acids comparative to controls followed by the growth of P. anaerobius and 
amino acids utilization. Moreover, supplementation of the growth medium with amino 
acids in concentrations similar to those accessible after prior growth with P. bivia had a 
growth-stimulatory effect on P. anaerobius. Thus, increased availability of amino acids 
was suggested as a mechanism to support the commensal synergism of P. bivia with P. 
anaerobius. Another in vitro study supported the synergistic role between these two 
species, with Gardnerella spp. enhancing the growth of P. anaerobius when a tryptic 
soy agar medium supplemented with 0.5% glucose was used (Teixeira et al. 2010). 
Whereas these are in vitro observations, studies performed in vivo also demonstrated the 
existence of potential synergies among vaginal microorganisms involved in BV. 
Accordingly, by investigating the composition and spatial organization of bacteria in 
biopsy specimens from patients with BV, Swidsinski and colleagues found that A. 
vaginae was homogeneously intermixed with Gardnerella spp. in an adherent biofilm 
specific for this condition. Gardnerella spp. was the predominant species in the biofilm, 
followed by A. vaginae, which composed up to 40% of the biofilm mass (Swidsinski et 
al. 2005). Later, Hardy and colleagues confirmed the synergy between Gardnerella spp. 
and A. vaginae in samples with BV-biofilms from participants from a clinical trial in 
Rwanda (Hardy et al. 2016). Additionally, synergistic interactions between Gardnerella 
spp. and Mycoplasma hominis (Cox et al. 2016) or A. vaginae and Prevotella spp. 
(Datcu et al. 2013) have been also demonstrated in clinical samples. 
Contrary to synergistic interactions which are beneficial for the microorganisms present 
in the vaginal environment, antagonistic interactions result in a negative effect for at 
least one species (Moons, Michiels and Aertsen 2009). Antagonistic interactions among 
organisms within a community are unavoidable due to competition for nutrients, with 
effects on the viability and growth of competitors, or preference for colonization of new 
surfaces (Stubbendieck, Vargas-Bautista and Straight 2016). Within the vagina, these 
antagonistic interrelationships have been also observed, being described that production 
of lactic acid by lactobacilli have a detrimental effect on many BV-associated species 
(Amabebe and Anumba 2018a). This effect has been only discussed in a few in vivo 
studies, but there are many in vitro experiments that have addressed the antagonism 
effect between lactobacilli and bacteria involved in BV. Thus, starting with early studies 
(Skarin and Sylwan 1986; Nagy, Petterson and Mardh 1991) and continuing to the most 
recent ones (Bertuccini et al. 2017), it has been demonstrated that different 
Lactobacillus spp. inhibit the growth and adhesion on epithelial cells of several bacterial 
species cultured from the vaginal content of women with BV, as described in Table 5. 
Additionally, using an ex vivo porcine vaginal mucosal model, Breshears and colleagues 
demonstrated that L. crispatus is able to produce lactic acid and inhibits the growth of 
Gardnerella spp. in co-colonization experiments (Breshears et al. 2015). However, the 
molecular mechanisms by which Lactobacillus spp. interact with pathogenic vaginal 
bacteria and host cells are still largely unknown (Younes et al. 2018). A future direction 
of these studies could be to examine metabolic, adhesion and coaggregation processes 
that maintain the biofilms, as well as to determine the proteome and transcriptome of 
these bacterial communities.  
Interactions between Gardnerella spp. and other STIs agents 
As described above, BV is characterized by a polymicrobial biofilm where BV-
associated species establish synergistic interactions, that include (i) co-aggregation 
(Rickard et al. 2003), (ii) metabolic cooperation (Castro et al. 2017), (iii) increased 
resistance to antibiotics (Bradshaw and Sobel 2016) or (iv) to the host immune response 
(Castro, Jefferson and Cerca 2018). Such bacterial interspecies cooperation could have 
important clinical implications, causing persistent, slowly progressing and chronic 
infections (Lebeaux, Ghigo and Beloin 2014; Hardy et al. 2017). Additionally, as 
discussed previously, there is epidemiological data linking BV-associated microbiota to 
the acquisition of STIs (Gallo et al. 2012), suggesting that BV-associated bacteria and 
STIs agents can establish ecological interactions, as briefly described in Table 6. 
Together, this raises an interesting question: can STIs agents incorporate the 
Gardnerella spp. biofilm and increase the risk of reproductive health complications? In 
order to answer this question, Filardo and colleagues analyzed the ecological 
interactions between Gardnerella spp. and C. trachomatis (Filardo et al. 2019). They 
proposed that biofilm-related Gardnerella spp. genital infections may act as a reservoir 
of C. trachomatis and, thus, contribute to the transmission of the infection in the 
population, as well as to its dissemination into the upper genital tract, increasing the risk 
of developing severe reproductive sequelae (Filardo et al. 2019). The strong relationship 
between BV and chlamydial infections highlights the importance of normal vaginal 
microbiota in the defense against STIs acquisition. 
It is also noteworthy that the wide panoply of BV-associated pathogens influences the 
epithelial homeostasis, through the reduction of the cervicovaginal fluid viscosity due to 
the production of mucin-degrading enzymes (Wiggins et al. 2001). These enzymes, 
such as sialidases, α-fucosidase, α- and β- galactosidase, N-acetyl-glucosaminidase, 
glycine and arginine aminopeptidases are involved in the degradation of the gel layer 
coating the cervical epithelium, causing micro-abrasions or alterations of epithelial cells 
(Olmsted et al. 2003; Moncla et al. 2015). Therefore, such enzymes may promote 
virulence through destroying the protective mucosa barrier and hence increase 
susceptibility to C. trachomatis and N. gonorrhoeae colonization (Wiesenfeld et al. 
2003) and viral STIs microbes (Gillet et al. 2011; Borgdorff et al. 2016). Specifically, it 
was verified that such detrimental changes in the mucosal barrier could facilitate 
cervical HPV infection by facilitating adherence, invasion and eventually incorporation 
of HPV oncogenes into the genome of cells of the transformation zone (Gillet et al. 
2011). Of note, abnormal vaginal microbiota could also be implicated in the 
maintenance of subclinical HPV (Gillet et al. 2011). Similar to what is described for 
HPV, an increased acquisition of HIV has been also associated with detrimental 
changes caused by Gardnerella spp. and other vaginal pathogens to the mucosal barrier 
(Borgdorff et al. 2016). Also, during T. vaginalis colonization, it was demonstrated an 
enhancement of the paracellular permeability of the cervicovaginal epithelium by 
disturbing the integrity of the tight junction complex caused as a result of co-
colonization with Gardnerella spp. and other CST-IV bacteria (Hinderfeld et al. 2019). 
Aside from these studies, most of the other investigations that focus on the interaction 
between Gardnerella spp. and STIs agents are associated with the inflammatory 
response. The changes in immune homeostasis could be induced through different 
mechanisms: production of pro-inflammatory cytokines (Kremleva and Sgibnev 2016) 
or recruitment of immune cells (Torcia 2019). In this sense, the preexisting mucosal 
immune milieu at the site of sexual STIs agents exposure is a key determinant of STIs 
acquisition risk (Kaul et al. 2015). Interestingly, there is one study that provides 
evidence for a cause-effect relationship between trichomoniasis and BV (Fichorova et 
al. 2013). On the one hand, T. vaginalis, Gardnerella spp., and A. vaginae amplified 
pro-inflammatory responses by inducing increased interleukin (IL)-8 production. On the 
other hand, co-infections with these microbes seem to influence the protective innate-
immune responses by suppressing the secretory leukocyte protease inhibitor (Fichorova 
et al. 2013), an antimicrobial peptide responsible for the protection of local tissue 
against the detrimental consequences of inflammation. 
Regarding HSV-2 infection, the biological mechanism that is responsible for its 
association with vaginal dysbiosis is not clear (Torcia 2019). However, there is some 
evidence showing that the intermittent HSV-2 reactivation leads to immune activation 
in the genital environment, favoring changes in microbiota composition and epithelial 
shedding (Cherpes et al. 2005; Van de Perre et al. 2008; Torcia 2019). Such changes in 
the vaginal environment might be inhospitable to healthy microbiota and therefore 
could be an underappreciated but important risk for incident BV (Esber et al. 2015). 
Finally, Gardnerella spp. and other BV-associated bacteria seem to increase HIV 
acquisition risk by inducing genital inflammation (Anahtar et al. 2016; Gosmann et al. 
2017). This can occur due to two possible mechanisms: (i) proinflammatory cytokines, 
such as IL-1α and TNF-α, are produced after stimulation of innate immune receptors on 
both epithelial cells and local dendritic cells (Bamias, Arseneau and Cominelli 2014; 
Anahtar et al. 2016) or (ii) genital antigen-presenting cells sense activated bacterial 
products, in particular LPS, produce cytokines and chemokines which increase the 
recruitment of activated CD4+ lymphocytes (Anahtar et al. 2016). Together, these 
experiments highlight the importance of understanding the interactions between vaginal 
microbiota and STIs agents.  
Taking into account that BV is associated with the increased risk of STIs acquisition, it 
has been suggested that interventions targeting genital microbiota, by using effective 
microbicides, might reduce STIs acquisition in women. However, more mechanistic 
studies are needed in order to leverage these interactions to improve prevention and 
treatment strategies. 
HOW POLYMICROBIAL INTERACTIONS INFLUENCE ANTIMICROBIAL THERAPY? 
With the knowledge that BV is associated with a polymicrobial biofilm, there was an 
emergent need to start focusing on investigating the effect of antibiotics on in vivo and 
in vitro developed BV biofilms in order to improve the treatment options. 
Unfortunately, available studies addressing this subject are still scarce, and to date, as 
far as we are aware, no studies have been reported in how polymicrobial interactions 
can enhance antimicrobial tolerance in BV (Hardy et al. 2017; Jung et al. 2017). 
Nevertheless, relevant information can be inferred from the studies concerning 
polymicrobial communities that have been explored antimicrobial activity in otitis 
media (Perez et al. 2014) or in cystic fibrosis (Lopes et al. 2012; Lee et al. 2014; 
Manavathu, Vager and Vazquez 2014).  
When assessing the impact of polymicrobial interactions in cases of otitis media, Perez 
and colleagues demonstrated that dual-species biofilms formed by Moraxella 
catarrhalis and Streptococcus pneumoniae have offered both bacteria the advantage of 
being more resistant to β-lactam antibiotics and bacterial clearance. These authors 
showed that β-lactamase produced by M. catarrhalis provided passive protection to S. 
pneumoniae against amoxicillin killing, while S. pneumoniae protected M. catarrhalis 
from azithromycin killing by an unknown mechanism (Perez et al. 2014). Lopes and 
colleagues demonstrated that Dolosigranulum pigrum and Inquilinus limosus, two 
unusual antibiotic-sensitive species isolated from the airways of patients with cystic 
fibrosis, became significantly more tolerant to several antibiotics, including gentamicin, 
levofloxacin, and clindamycin, upon co-culture in biofilm conditions with Pseudomonas 
aeruginosa (Lopes et al. 2012). Likewise, mixed-species biofilms composed of P. 
aeruginosa, Pseudomonas fluorescens, and Klebsiella pneumoniae were more tolerant 
to tobramycin and sodium dodecyl sulfate surfactant compared to mono-species 
biofilms, suggesting that increased tolerance stems from a cross-protection beneficial to 
the entire community (Lee et al. 2014).
Other studies carried out on bacterial-fungi interactions also demonstrated an increased 
tolerance to antibiotics. Manavathu and colleagues developed a dual-species biofilm of 
P. aeruginosa and Aspergillus fumigatus, both highly prevalent in the airways of cystic 
fibrosis patients, and revealed that P. aeruginosa cells associated with the dual-species 
biofilms had reduced susceptibility to cefepime compared to those of mono-species 
biofilms, while A. fumigatus demonstrated similar antifungal drug susceptibility in 
mono- and dual-species biofilms (Manavathu, Vager and Vazquez 2014). Other 
investigations that showed an increased antimicrobial tolerance in dual-species biofilms, 
compared to mono-species, are the studies between C. albicans and E. coli (De Brucker 
et al. 2015) or C. albicans and S. aureus (Harriott and Noverr 2009). In both cases, the 
biofilm matrices and extracellular polymeric substances provided cross-species 
protection. Accordingly, C. albicans exopolysaccharide, β-1,3-glucan, can bind with 
ofloxacin, and E. coli cells embedded within C. albicans biofilms were found to have 
increased tolerance to ofloxacin compared to E. coli mono-species biofilms (De Brucker 
et al. 2015). A similar situation was observed for the mixed biofilms of C. albicans and 
S. aureus, where S. aureus cells coated in the matrix secreted by C. albicans showed 
enhanced tolerance to vancomycin (Harriott and Noverr 2009).  
Based on these previous studies, we hypothesize that in BV-associated biofilms, similar 
interactions could also occur. Such possibility is supported by in vivo studies. Bradshaw 
and colleagues followed up 139 women with BV that were treated with oral 
metronidazole and examined at 1, 3, 6, 12 months or until they reached a Nugent score 
of 7-10 and recurrence of Gardnerella spp. and A. vaginae infection was established. 
Their results showed that recurrence rates of BV were significantly higher in women 
colonized with both Gardnerella spp. and A. vaginae (83%), as compared to women 
infected with Gardnerella spp. but not A. vaginae (38%), suggesting that the association 
between these 2 bacteria enhanced the tolerance to metronidazole, with direct impact on 
treatment failure (Bradshaw et al. 2006b). Other in vivo study, in which 18 patients 
diagnosed with BV were treated with oral regime of metronidazole for 1 week, showed 
that the vaginal polymicrobial Gardnerella spp. biofilm was temporarily suppressed 
during metronidazole treatment, but quickly recovered its activity following treatment 
interruption (Swidsinski et al. 2008). Importantly, Swidsinski and colleagues found that 
high numbers of Gardnerella spp. and A. vaginae were present on the vaginal epithelial 
cells during the follow-up examination, further highlighting a possible synergism 
between these two species, regarding antimicrobial tolerance.  
Considering in vivo observations, antimicrobial therapy failure and high recurrence 
levels of BV can be also explained by some in vitro studies. Not surprisingly, most of 
the in vitro experiments addressing antimicrobial therapy are focused on Gardnerella 
spp. Back in 1985, it was already demonstrated that of 11 Gardnerella spp. isolates, 4 
were resistant to metronidazole (Jones et al. 1985). More recently, another study has 
demonstrated that Gardnerella spp. presents high in vitro resistance rates to 
metronidazole with a MIC value of >128 µg mL
-1
 (Anukam and Reid 2008).
Furthermore, a study conducted in our research group analyzing 14 isolates of 
Gardnerella spp. showed that all isolates tested were resistant to metronidazole, while 
almost 36% and 86% of the isolates were resistant to clindamycin and tinidazole, 
respectively (Castro et al. 2015).  
Besides Gardnerella spp., there are also a few studies addressing other common BV-
associated species, such as A. vaginae and Mobiluncus spp. Noteworthy, in vitro 
resistance of A. vaginae to metronidazole was demonstrated in up to 50% of the isolates 
tested (Ferris et al. 2004; De Backer et al. 2006, 2010). Regarding Mobiluncus spp., 
resistance to metronidazole has been found to be more prevalent in M. curtisii (up to 
100% of the isolates tested) than in M. mulieris (less than 50% of the isolates tested) 
(Spiegel 1987; Bahar et al. 2005). Alves and colleagues also showed that many other 
BV-associated bacteria have in vitro resistance to metronidazole (Alves et al. 2014), 
however, that study only tested 1 strain per species and, therefore, the prevalence of this 
phenomena could not be assessed. 
Regarding the impact of clinically approved antibiotics on BV-associated in vitro 
biofilms, only a few papers have been described so far. The first study to assess 
clindamycin efficiency in Gardnerella spp. biofilms found that 1600 µg mL
-1
 was able
to reduce up to 2-log of the viable cell count in preformed biofilms (Turovskiy et al. 
2012). Higher concentrations of either metronidazole (2000 µg mL
-1
) or clindamycin
(20000 µg mL
-1
) were able to kill biofilm-associated Gardnerella spp. cells after 8 h of
incubation (Algburi, Volski and Chikindas 2015). Afterwards, Thellin and colleagues 
demonstrated that concentrations of 600 µgmL
-1
 and 100 µg mL
-1
 of metronidazole and
clindamycin, respectively, administered on 72 h biofilms of Gardnerella spp. were 
sufficient to achieve 100% cells mortality (Thellin et al. 2016). Despite the apparent 
success of these in vitro experiments, the concentrations used in those studies were a lot 
higher than the peak serum concentrations (Ralph et al. 1974; Dan, Yampolsky and 
Poch 1997) and therefore could not be used in treatment. When using clinically 
achievable concentrations, Gottschick and colleagues found that metronidazole (0.001 
µg mL
-1
) had the ability to prevent the development of Gardnerella spp. biofilms, if
used preemptively, but could not disrupt the existing biofilms and did not affect the 
viability of their cells (Gottschick et al. 2016). 
Interestingly, the evidence found in vitro biofilms is supported by our recent study in 
which we have found that genes involved in antimicrobial resistance were up-regulated 
in Gardnerella spp. biofilm cells (Castro et al. 2017). Moreover, we later observed that 
this up-regulation of genes was further enhanced in specific dual-species BV biofilms 
(Castro, Machado and Cerca 2019), providing some mechanistic evidence that explains 
why some polymicrobial communities might have increased antimicrobial resistance 
and, consequently, lead to BV recurrence, which has been associated with the chronic 
nature of this infection. Overall, understanding the molecular basis and biological effect 
of these inter-bacterial processes may provide novel information necessary to define 
new targets and strategies for BV control. 
Importance of novel strategies to fight chronic vaginal infections 
Similar to what was described above for BV, increased cases of recurrence are being 
observed in other vaginal infections (Seña, Bachmann and Hobbs 2014; Denning et al. 
2018). This is of particular concern because we are already heading toward a post-
antibiotic era in which many bacterial infections will be impossible to treat (Hauser, 
Mecsas and Moir 2016). The same situation can be expected for fungal infections 
(Casadevall, Kontoyiannis and Robert 2019), whose recurrence affects millions of 
women worldwide, being a common cause of significant morbidity among them (Sobel 
2016). Unluckily, the case of viral vaginitis is not far from the above-mentioned 
situations with viruses being resistant to the common antiviral drugs, and the preventive 
therapies which are represented by vaccines still in development for some of them 
(Johnston, Gottlieb and Wald 2016; Safrit et al. 2016).  
Concerning this issue, there are several attempts to use diverse compounds such as 
antimicrobial therapy adjuvants, in order to increase the efficacy of the common 
antibiotic treatment. These adjuvants, when used alone have little antimicrobial activity, 
but when co-administered with antibiotic, they either (i) block the main bacterial 
resistance mechanisms or (ii) enhance the antimicrobial action of the drug (González-
Bello 2017). In this regard, several clinical studies supported the concept that 
lactobacilli can work as antimicrobial adjuvants since they able to increase the efficacy 
of metronidazole (Anukam et al. 2006; Larsson et al. 2011; Bodean et al. 2013; Heczko 
et al. 2015). Interestingly, the utilization of DNase in combination with metronidazole 
led to greater Gardnerella spp. biofilm disruption than either agent alone (Hymes et al. 
2013). A similar study demonstrated that lysozyme in combination with metronidazole 
or clindamycin also improved the antimicrobial activity of the tested agents against 
Gardnerella spp. in vitro biofilms (Thellin et al. 2016). Algburi and colleagues also 
showed that natural antimicrobials subtilosin and lauramide arginine ethyl ester 
exhibited a synergistic effect with metronidazole and clindamycin when applied on 
biofilms of Gardnerella spp. (Algburi, Volski and Chikindas 2015). Moreover, more 
recently, it was shown that cationic amphiphiles displayed a positive effect either with 
metronidazole or clindamycin against BV-associated bacteria (Algburi et al. 2017; 
Weeks et al. 2019). 
Besides the fact that these therapeutic strategies are promising, there are also attempts to 
totally replace current antibiotic treatment, as described in Table 7 and as it has been 
recently reviewed (Machado et al. 2016; Falconi‐McCahill 2019). However, many of 
the alternative approaches tend to achieve a reduction of the symptoms, instead of being 
targeting directly the causes of BV, with little attention being put in the microbial 
interactions occurring during disease. As discussed before, the vaginal environment in 
disease is a complex niche being governed by still poorly understood relationships 
among the present microbial species. Therefore, it is of utmost importance to focus 
attention on how the microbial interactions in BV and other vaginal infections are 
affecting antimicrobial therapies, in order to speed up the process of finding and 
developing novel treatment or preventive strategies effective against recurrent vaginal 
infections. 
GARDNERELLA SPP. BEYOND BV 
Apart from vaginal infections, Gardnerella spp. has also been found in other types of 
infections. However, in some of these situations, it is neither clear what is the origin of 
the microorganism nor the mode of transmission and its role in the infection. Globally, 
when Gardnerella spp. is detected in infections occurred in women, often it is also 
reported a gynecological condition or procedure that could be the event leading to the 
development of infection. In cases of infection in men, a possible sexual transmission or 
UTIs can be the cause. 
Gardnerella spp. association to UTIs have been described both in women and men. 
Some studies have demonstrated that UTIs are more common in women suffering from 
BV (Hillebrand et al. 2002; Sharami, Afrakhteh and Shakiba 2007; Sumati and Saritha 
2009). However, one important limitation of these studies is the fact that it is not 
reported whether the development of the UTI is preceded by BV or vice-versa. The 
proximity of the vaginal canal with the urinary tract and the microbial alterations 
characteristic of BV, with an overgrowth of pathogenic bacteria and the lack of 
protecting microbiota, might allow the colonization with uropathogens and 
consequently facilitate women to develop UTIs (Lam, Birch and Fairley 1988; 
Harmanli et al. 2000; Kline and Lewis 2016). Further studies support the increased 
ability of women with BV to develop UTIs, showing that the artificial colonization of 
vagina with Lactobacillus, by means of probiotic treatment with L. crispatus, may be 
beneficial for women prone to recurrent UTIs (Stapleton et al. 2011). In the context of 
UTIs, Gardnerella spp. involvement was associated with different health problems 
including balanoposthitis (Kinghorn et al. 1982), pyelonephritis (Pritchard 2018), 
cystitis and prostatitis (Sturm 1989). 
Other clinical situations where Gardnerella spp. has been detected was in bloodstream 
infections in women in the context of vaginal infections (Tankovic et al. 2017), 
pregnancy (Flórez et al. 1994), gynecological procedures that may introduce the 
bacterium in the bloodstream (Agostini et al. 2003; McCool and DeDonato 2012), or in 
immunocompromised patients (Saikali et al. 2017). Curiously, there has been one 
reported case of bacteremia in a newborn, where the mother was diagnosed with 
endometritis and the transmission of Gardnerella spp. probably occurred by aspiration 
of maternal amniotic fluid (Amaya, Al-Dossary and Demmler 2002). Furthermore, 
while rare, bloodstream infections caused by Gardnerella spp. have been reported in 
men (Legrand et al. 1989; Lagacé-Wiens et al. 2008). In one report, an uncircumcised 
man, with a previous history of diabetes mellitus and hypertension and whose sexual 
partner had recurrent BV was infected with Gardnerella spp. having serious 
consequences on vital organs, with the development of infective endocarditis and 
emboli in the kidney and brain (Yoon et al. 2010). In another case, the patient was 
affected with the development of multiple abscess affecting the lungs and kidney, but 
no predisposing factors were found (Calvert, Collins and Bateman 2005). 
The presence of Gardnerella spp. in osteoarticular infections has also been detected, 
such as in acute hip arthritis (Sivadon-Tardy et al. 2009), disk space infections (Hodge, 
Levy and Smith 1995), discitis and vertebral osteomyelitis (Graham et al. 2009), 
osteomyelitis and hip abscess (Shah, Nanjappa and Greene 2017), joint infections 
(Hoarau et al. 2012), reactive arthritis (El Mezouar et al. 2014), and spinal epidural 
abscesses (Stewart et al. 2018). Gardnerella spp. is also reported as the pathogen 
involved in some infrequent infections such as wound infection (Sturm, de Leeuw and 
de Pree 1983), tubo-ovarian abscess (Burgess, Daramola and Lacey 1997), meningitis 
(Berardi-Grassias et al. 1988), retinal vasculitis (Neri et al. 2009), cephalohematoma 
(Nightingale et al. 1986), and hydropneumothorax (Murray et al. 2019).  
As discussed above, some antimicrobial agents are indicated for the treatment of BV. 
Regarding extra-vaginal infections where Gardnerella spp. is involved, there is no 
consensus in the recommendation for treatment. Overall, in the cases reviewed, the 
patient was initially treated with broad-spectrum antibiotics such as ampicillin. When 
the microorganism was identified as Gardnerella spp., often the treatment was changed 
to include metronidazole or clindamycin therapy.  
CONCLUDING REMARKS 
The vaginal microbiota plays a mutually beneficial relationship with their host and has a 
major impact on health and disease. Despite various studies have already addressed the 
importance of the vaginal microbiota and its relationship with vaginal infections and 
STIs, studies on the interactions among the microbial populations are lagging behind. In 
a context of dysbiosis of the vaginal microbiota, Gardnerella spp. seems to have a 
special role, since this bacterium is highly detected in BV, the most prevalent vaginal 
infection worldwide. However, other microbes can also colonize the vaginal ecosystem, 
establishing ecological interactions with Gardnerella spp., which include the examples 
documented in this review.  
Despite all the efforts to unveil the mechanisms involved in the interactions among 
vaginal microbes, the biological relevance of such interactions remains largely 
unknown. Because the vaginal epithelium is an important entry point for microbes, 
including to STIs agents, a deeper understanding of the mechanisms of adhesion and 
signaling involved in polymicrobial interactions will provide a new perspective on the 
role of known virulence determinants. Furthermore, instead of infection being thought 
of as a defined host-pathogen relationship, it should be envisioned as a spectrum of 
host-microbe pathogenic mechanisms, microbe-microbe interactions, host immunity-
mediated antimicrobial defenses, and environmental factors. As such, future studies 
should focus on exploring mechanistic in vitro models as well as implementing animal 
model systems to study polymicrobial vaginal interactions in order to understand the 
complex dynamics within mixed microbial communities and their importance during 
interactions with the host.  
The key challenges now are to unravel precise details of the unique biology of 
polymicrobial interactions under conditions of co-existence in the vagina. With the 
application of powerful RNA-sequencing, DNA microarray, proteomic, and 
metabolomics technologies, there are now tools available to undertake such efforts. The 
identification of potential targets for the inhibition of co-adhesion and biofilm 
development may ultimately provide the means to modify microbial vaginal 
colonization and thus reduce the impact of polymicrobial diseases on women health. 
This might form the basis for novel, ecologically-based strategies for the control of 
vaginal infections, other than the current use of antimicrobial agents, which are 
associated with high recurrence rates. 
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Figure 1. Representation of the different ethnic groups of women within each 
community state type (CST) proposed by Ravel et al. 2011. The study cohort consisted 
of 96 Asian women, 97 white women, 104 black women, and 97 Hispanic women, 
showing the relationship between ethnic background and vaginal bacterial community 
composition.  
Figure 2. Schematic representation of the healthy and unbalanced vaginal microbiota 
according to the most common vaginal infections. 
Figure 3. Representation of the putative model of BV infection. 
Figure 4. Gram-staining vaginal smears illustrate the vaginal microbiota. (a) Normal 
vaginal epithelial cells. (b) Intermediate vaginal microbiota. (c) BV-associated 
microbiota, showing a vaginal clue cell, which corresponds to vaginal squamous 
epithelial cells coated with Gardnerella spp. and other anaerobic bacteria. Original 
magnification: 1000 times. 
Figure 5. Representation of the epidemiological profile of BV in relation to sexual 
behavior. This figure was created based on the information presented in the article by 
Verstraelen et al. 2010. 
Figure 6. Conceptual multi-species model of the BV-associated biofilm development. 
In multi-species BV-related biofilms, secondary pathogens are able to incorporate the 
initially formed biofilm by Gardnerella spp. which is already adhered to the vaginal 
epithelium. Following, a synergistic relationship can be formed, allowing the biofilm to 
prosper. 
Table 1. Main features of the normal vaginal microbiota and the most common vaginal 
infections. 
Vaginal 
fluid 
Vaginal 
fluid pH 
Clinical 
inflammation 
and 
symptoms 
Microscopic 
features 
Sexually 
transmitte
d 
References 
Healthy White, no or 
milky odor, 
variable 
viscosity 
along the 
cycle 
3.5 – 4.5 No Mainly 
normal 
intermediate 
and 
superficial 
vaginal cells, 
numerous 
lactobacilli, 
very scarce 
leukocytes 
Not 
applicable 
(Frobenius and Bogdan 
2015; Palmeira-de-
Oliveira, Palmeira-de-
Oliveira and Martinez-
de-Oliveira 2015; 
Sherrard et al. 2018) 
Bacteria
l 
vaginosi
s 
Abundant, 
whitish gray, 
rotten fish 
odor, low 
viscosity 
> 4.5 Odorous 
discharge (or 
no symptoms 
at all), absence 
of redness; no 
or slight 
inflammation 
Clue cells, 
scarce or no 
lactobacilli, 
no 
leukocytes, 
abundant 
bacteria 
Controvers
ial 
(Frobenius and Bogdan 
2015; Palmeira-de-
Oliveira, Palmeira-de-
Oliveira and Martinez-
de-Oliveira 2015; 
Sherrard et al. 2018) 
Aerobic 
vaginitis 
Abundant 
watery, 
yellow, no 
fish odor, 
low 
viscosity 
> 4.5 Erythema Scarce or no 
lactobacilli, 
leukocytes, 
abundant 
bacteria 
No (Donders et al. 2002; 
Frobenius and Bogdan 
2015; Palmeira-de-
Oliveira, Palmeira-de-
Oliveira and Martinez-
de-Oliveira 2015; 
Sherrard et al. 2018) 
Vulvova
ginal 
candidia
sis 
White, none 
or ferment 
odor, 
“cottage 
cheese-like”, 
creamy or 
floccular, 
high 
viscosity 
3.5 – 4.5 Diffuse 
redness, 
swelling and 
fissuring to the 
vulva, burning 
and pruritus 
Some deeper 
vaginal cells 
present, 
variable 
number of 
lactobacilli 
and 
leukocytes, 
blastoconidi
a and 
pseudohypha
e 
No (Sobel 2007; Frobenius 
and Bogdan 2015; 
Palmeira-de-Oliveira, 
Palmeira-de-Oliveira and 
Martinez-de-Oliveira 
2015; Sherrard et al. 
2018) 
Tricho
moniasi
s 
Yellow/ 
green 
aqueous 
discharge, 
fishy/ putrid 
odor, low 
viscosity 
> 4.5 Erythema, red 
plaques, 
vulvar 
irritation and 
pruritus 
Protozoa 
identificatio
n, 
particularly 
if motile 
numerous 
bacteria and 
leukocytes, 
many 
parabasal 
cells 
Yes (Palmeira-de-Oliveira, 
Palmeira-de-Oliveira and 
Martinez-de-Oliveira 
2015; Edwards et al. 
2016; Sherrard et al. 
2018) 
Table 2. Association of BV with other vaginal infections. 
Bacterial vaginosis (BV) References 
AEROBIC VAGINITIS (AV) 
Mixed situations (AV and BV) can be found, representing either a transient form or 
prolonged co-infection  
(Vieira-Baptista et al. 2016; 
Donders et al. 2017) 
VULVOVAGINAL CANDIDIASIS (VVC) 
VVC is a common side effect of BV treatment with antibiotics, indicating that the 
vaginal microbiota might be related to the colonization of yeast 
(Pirotta, Gunn and Chondros 
2003) 
Co-colonization of Candida spp., Gardnerella spp. and other BV-associated bacteria 
on Pap smears 
(Wei et al. 2012) 
TRICHOMONIASIS 
Co-occurrence of trichomoniasis and BV was found in approximately half of women 
infected with Trichomonas vaginalis  
(Sutton et al. 2007) 
Vaginal microbiota belonging to CST-IV was significantly associated with T. 
vaginalis detection 
(Brotman et al. 2012) 
T. vaginalis vaginal colonization had a negative impact in lactobacilli but not in BV-
associated species 
(Fichorova et al. 2013) 
Nugent score higher than 3 was associated with a significantly increased risk of 
acquiring trichomoniasis 
(Balkus et al. 2014) 
CHLAMYDIA/ GONORRHEA 
Women with BV were 3.4 times more likely to test positive for chlamydia and 4.1 
times more likely to test positive for gonorrhea compared to women without BV  
(Wiesenfeld et al. 2003) 
Incident chlamydia/ gonorrhea was associated with BV severity, as measured by a 
high Nugent score (8–10) 
(Allsworth and Peipert 2011) 
Women with a BV-associated microbiota experiencing a 2-fold increased risk for 
STIs compared to women with normal vaginal microbiota 
(Allsworth and Peipert 2011) 
Antecedent episodes of BV are associated with an increased risk of subsequent 
chlamydia and gonorrhea infection  
 (Bautista et al. 2017) 
VIRAL VAGINITIS 
Nugent scores of 4 or higher were significantly associated with a 32% increase in 
concurrent herpes simplex virus type 2 (HSV-2) and an 8% increase in HSV type 1 
(HSV-1)  
(Allsworth, Lewis and Peipert 
2008) 
BV was 60% greater prevalent among HSV-2-positive women when compared with 
HSV-2-negative women, implying HSV-2 infection is an important BV risk factor 
  (Esber et al. 2015). 
An increased association of prevalent and incident human papillomavirus (HPV) was 
shown in women with both intermediate and BV microbiota  
Watts et al. 2005; King et al. 
2011) 
Women who were HPV-positive had a lower proportion of protective vaginal (Lee et al. 2013; Brotman et 
Lactobacillus spp. when compared with HPV-negative women al. 2014). 
Vaginal dysbiosis with increased risk of acquisition and transmission of human 
immunodeficiency virus type 1 (HIV-1). A meta-analysis of 23 studies showed that 
BV was associated with a 60% increase in the risk of acquiring HIV-1  
(Atashili et al. 2008; Sturm-
Ramirez et al. 2000; Pyles et 
al. 2014; McKinnon et al. 
2019) 
Table 3. Scheme for grading Gram-stained vaginal contents. 
Score 
Lactobacillus 
Morphotypes 
Gardnerella and Bacteroides spp. 
Morphotypes 
Curved Gram-Variable Rods 
0 4+ 0 0 
1 3+ 1+ 1+ or 2+ 
2 2+ 2+ 3+ or 4+ 
3 1+ 3+ 
4 0 4+ 
VAGINAL MICROBIOTA DIAGNOSIS BY NUGENT SCORE SYSTEM 
Total score 
a
 Interpretation 
0 – 3 Normal vaginal microbiota 
4 – 6 Intermediate vaginal microbiota 
7 – 10 Bacterial vaginosis in vaginal microbiota 
a
 Morphotypes are scored as the average number see per oil immersion field. Quantification of each individual score: 0 for no 
morphotype present; 1+ for 1 morphotype present; 2+, 1 to 4 morphotypes present; 3+, 5 to 30 morphotypes present; 4+, 30 or 
more morphotypes present. The total score is the sum of the average classification of Lactobacillus, Gardnerella and 
Bacteroides, and finally Mobiluncus spp. Adapted from Nugent, Krohn and Hillier 1991. 
Table 2. Koch’s postulates and Gardner and Duke´s conclusions. 
Koch’s postulates (Koch 1876) Gardner and Duke observations 
(Gardner and Dukes 1955) 
1. The etiologic microbe should be
found in every case of the disease
1. 92% of patients with a primary
diagnosis of BV were found to
have H. vaginalis infection
2. The bacterium must be isolated
from a diseased organism and
grown on pure culture
2. This was accomplished in each of
the 141 cases with positive H.
vaginalis cultures
3. The etiologic microbe should be
isolated in pure culture on lifeless
media and be capable of causing
the characteristic disease anew
upon inoculation in a susceptible
host
3. A patient, known to be free of
disease, was inoculated with H. 
vaginalis. The patient developed 
clinical manifestations of the 
disease and the organism was 
recovered in pure culture 
4. The etiologic microbe should be
re-isolated from the
experimentally inoculated host
4. This requirement was fulfilled since
pure cultures of the bacterium were 
successfully obtained from the 
patient’s culture material 
Table 3. Bacterial interactions occurring in the context of BV and their predictive ecological 
effects. 
Microbes Interaction Mechanism Effect in host References 
SYNERGISM WITHIN MICROBES 
Gardnerella 
spp. and 
Prevotella 
bivia 
P. bivia 
produced 
ammonia which 
was utilized by 
Gardnerella 
spp. which 
produced amino 
acids that were 
utilized by P. 
bivia 
Ammonia and amino 
acids cycle 
Presence of high 
vaginal pH 
(Pybus and 
Onderdonk 
1997) 
Peptostreptoc
occus 
anaerobius 
and P. bivia 
Amino acids 
accumulation in 
P. bivia culture 
supernatants and 
subsequent 
growth of P. 
anaerobius in 
the conditioned 
supernatants 
P. anaerobius was 
able to grow in 
vaginal defined 
medium with P. 
bivia, but not in pure 
culture. Amino acids 
serve as a source for 
P. anaerobius growth 
Increased risk for 
female pelvic 
infections, adverse 
pregnancy outcome, 
and intra-amniotic 
infection 
(Pybus and 
Onderdonk 
1998) 
Gardnerella 
spp. and 
Atopobium 
vaginae 
A. vaginae was 
homogeneously 
intermixed with 
Gardnerella 
spp. in BV-
associated 
biofilms 
Unknown Presence of clue cells (Swidsinski et 
al. 2005) 
Gardnerella 
spp. and P. 
anaerobius 
Gardnerella 
spp. strains were 
able to enhance 
the growth of P. 
anaerobius 
Production of 
synergistic 
compounds by 
Gardnerella spp. 
Bacterial interactions 
present an important 
role in the ecology of 
the vaginal microbiota 
(Teixeira et al. 
2010) 
Gardnerella 
spp. and 
Eggerthella, 
Dialister sp. 
type 2, A. 
vaginae, and 
Aerococcus 
christensenii 
Metabolic co-
dependencies 
between these 
bacteria 
Unknown Possible contribution to 
increase the incidence 
of BV 
(Srinivasan et 
al. 2012) 
A. vaginae 
and 
Prevotella 
spp. 
Both bacterial 
species could 
have metabolic 
co-dependencies 
Unknown A combination of 
Prevotella spp. and/ or 
A. vaginae seems to 
diagnose BV with high 
accuracy 
(Datcu et al. 
2013) 
Gardnerella 
spp. and 
Fusobacteriu
m nucleatum, 
Mobiluncus 
mulieris, A. 
vaginae or P. 
bivia 
In vitro dual-
species biofilms 
of Gardnerella 
spp. derived a 
growth benefit 
from the 
addition of a 
second species, 
regardless of the 
species. 
Gardnerella 
spp. biofilms 
enhanced the 
growth of P. 
bivia and to a 
minor extent of 
F. nucleatum 
F. nucleatum was 
shown to be able to 
join an initial 
Gardnerella spp. 
biofilm (intermediate 
colonizer) 
The symbiotic 
relationships 
established between 
Gardnerella spp. and 
other anaerobes in BV 
biofilms could 
contribute to the 
progression of BV 
(Machado, 
Jefferson and 
Cerca 2013) 
Gardnerella 
spp. and 
Actinomyces 
neuii, 
Brevibacteriu
m 
ravenspurgen
se, 
Corynebacteri
um 
amycolatum, 
Corynebacteri
um 
tuscaniense, 
Staphylococc
us 
saprophyticus
, 
Enterococcus 
faecalis, 
Nosocomiicoc
cus ampullae, 
Staphylococc
us simulans, 
Staphylococc
us warnerii, 
Streptococcus 
anginosus, 
Propionibacte
rium acnes or 
Escherichia 
coli 
These bacterial 
species were 
able to cause an 
increase of the 
biomass of a 
pre-established 
Gardnerella 
spp. biofilm 
Unknown Could be associated 
with a high number of 
clue cells 
(Castro and 
Cerca 2015) 
Gardnerella 
spp. and A. 
vaginae 
Gardnerella 
spp. and A. 
vaginae are 
important 
constituents of 
the vaginal 
biofilm 
Unknown Presence of clue cells (Hardy et al. 
2016) 
Gardnerella 
spp. and E. 
coli or E. 
faecalis 
E. coli and E. 
faecalis were 
able to 
incorporate and 
enhance a pre-
formed 
Gardnerella 
spp. Biofilm 
In dual-species 
biofilms, these 
bacterial species 
seem to be able to co-
aggregate 
Uropathogens can 
associate in BV biofilm 
(Castro, 
Machado and 
Cerca 2016) 
Gardnerella 
spp. and 
Mycoplasma 
hominis 
Strong 
association 
between 
Gardnerella 
spp. and M. 
hominis were 
found in women 
with BV 
A potential quorum 
sensing-like 
interaction or co-
response to an 
environmental 
stimulus 
The transmission of 
one of these bacteria 
could trigger the 
outgrowth of the other 
and start a process 
leading to BV 
(Cox et al. 
2016) 
Gardnerella 
spp. and P. 
bivia 
Gardnerella 
spp. facilitated 
uterine infection 
by P. bivia 
The presence of 
Gardnerella spp. 
enhanced the invasive 
potential of P. bivia, 
facilitating its 
ascension into the 
uterus 
BV bacteria may 
actively inhibit 
inflammatory 
responses 
(Gilbert et al. 
2019) 
Gardnerella 
spp. and A. 
vaginae, A. 
neuii, C. 
tuscaniense, 
M. mulieris, 
S. anginosus, 
P. bivia, C. 
amycolatum, 
N. ampullae, 
P. acnes, B. 
ravenspurgen
se, E. 
faecalis, S. 
saprophyticus
, S. simulans, 
S. hominis, S. 
warnerii 
Despite all BV-
associated 
species were 
able to increase 
the cell number 
of a pre-
established 
Gardnerella 
spp. biofilm, not 
all bacterial 
species 
enhanced the 
Gardnerella 
spp. virulence 
according to 
transcriptomic 
findings 
Increased expression 
of genes associated 
with cytotoxicity, 
biofilm formation, 
antimicrobial 
resistance, and 
evasion of immune 
response by 
Gardnerella spp. in 
presence of specific 
BV-associated 
bacteria in dual-
species biofilms 
Bacterial interactions 
between co-infecting 
bacteria can profoundly 
affect the progress of 
BV and its clinical 
outcome 
(Castro, 
Machado and 
Cerca 2019) 
ANTAGONISM WITHIN MICROBES 
Lactobacillus 
spp. and 
Gardnerella 
spp., 
Mobiluncus 
spp., 
Bacteroides, 
and 
anaerobic 
cocci 
Lactobacillus 
inhibited the 
growth of 
bacteria isolated 
from women 
with BV 
The capacity of 
Lactobacillus to 
acidify the medium 
with a consequent 
decrease of pH and 
inhibition of growth 
Lactobacillus prevent 
the growth of bacteria 
associated with BV 
(Skarin and 
Sylwan 1986) 
Lactobacillus 
spp. and 
Gardnerella 
spp., 
Mobiluncus 
spp., 
Peptostreptoc
Lactobacillus 
inhibited the 
growth of 
Peptostreptococ
cus, M. curtisii, 
Gardnerella 
spp., and other 
The inhibition by 
Lactobacillus was 
influenced by the pH 
of the growth 
medium 
The interactions 
between Lactobacillus 
and other bacteria may 
regulate the 
microbiological 
ecosystem of the 
vagina 
(Nagy, 
Petterson and 
Mardh 1991) 
occus spp., 
Bacteroides 
spp. 
anaerobes 
Lactobacillus 
spp. and 
Gardnerella 
spp., 
Bacteroides 
spp., P. bivia 
Lactobacillus 
inhibited the 
growth of 
bacteria 
Production of acids 
and hydrogen 
peroxide (H2O2) by 
lactobacilli 
Lactobacilli would 
prevent colonization by 
other bacteria 
associated with BV 
(McLean and 
Rosenstein 
2000) 
Lactobacillus 
acidophilus 
and 
Gardnerella 
spp. 
L. acidophilus 
produced a 
bacteriocin that 
inhibited the 
growth of 
Gardnerella 
spp. isolates 
Production of a 
bacteriocin by L. 
acidophilus 
Lactobacilli, by the 
production of 
bacteriocins, have the 
capacity to prevent the 
growth of pathogenic 
bacteria 
(Aroutcheva, 
Simoes and 
Faro 2001) 
Lactobacillus 
helveticus 
and 
Gardnerella 
spp. and P. 
bivia 
L. helveticus 
inhibited the 
growth and 
viability of 
Gardnerella 
spp. and P. bivia 
and also 
decreased the 
capacity of 
adhesion of 
Gardnerella 
spp., to HeLa 
cells 
The antagonistic 
activity is due to the 
compounds produced 
by L. helveticus 
L. helveticus is a 
potential probiotic 
strain 
(Atassi et al. 
2006a) 
Lactobacillus 
spp. and 
Gardnerella 
spp. and P. 
bivia 
Lactobacillus 
strains isolated 
from vaginas of 
healthy women 
showed 
antagonistic 
activity against 
Gardnerella 
spp. and P. bivia 
in co-culture 
and also 
inhibited 
viability and 
adhesion of 
bacteria to HeLa 
cells 
Production of H2O2 
and proteolytic 
enzyme-resistant 
compounds by 
Lactobacillus spp. 
Lactobacillus can 
control the vaginal 
microbiota and 
compete with other 
organisms for the 
adherence to epithelial 
cells 
(Atassi et al. 
2006b) 
Lactobacillus 
spp. and 
Gardnerella 
spp. 
Lactobacillus 
have the 
capacity to 
displace and kill 
Gardnerella 
spp. growing as 
biofilm 
The production of 
H2O2 by some 
Lactobacillus strains 
seems to be the 
primary effect, 
however for some 
non-producer strains 
the production of 
biosurfactants, 
bacteriocins and 
signalling molecules 
may have effect on 
the displacement and 
Lactobacillus strains 
have the ability to 
disrupt biofilms that 
occur during BV and 
potentially reduce the 
need to antibiotics. 
Indigenous lactobacilli 
may have a restorative 
function to maintain a 
healthy vaginal 
microbiota 
(Saunders et al. 
2007) 
viability of 
Gardnerella spp. 
Lactobacillus 
rhamnosus 
and 
Gardnerella 
spp. and P. 
bivia 
Lactobacillus 
showed 
bactericidal 
activity against 
Gardnerella 
spp. and P. bivia 
It probably includes 
the production of 
hydrogen peroxide, 
lactic acid, and 
antibacterial 
compounds by 
Lactobacillus 
L. rhamnosus is 
considered a probiotic 
strain - a promising 
candidate for use in BV 
therapy 
(Coudeyras et 
al. 2008) 
Lactobacillus 
spp. and 
Gardnerella 
spp., P. bivia, 
Mobiluncus 
spp., and 
Bacteroides 
fragilis 
Lactobacillus 
species inhibited 
the growth of 
Gardnerella 
spp., P. bivia, 
and Mobiluncus 
spp., but did not 
show effect 
against B. 
fragilis 
Production of lactic 
acid, H2O2, and 
bacteriocins by 
Lactobacillus spp. 
Potential role of 
lactobacilli against BV 
pathogens 
(Matu et al. 
2010) 
Lactobacillus 
johnsonii, 
Lactobacillus 
gasseri and 
Gardnerella 
spp. 
Lactobacilli 
inhibited the 
growth of 
Gardnerella 
spp. 
Production of lactic 
acid, H2O2, and heat-
stable molecules by 
lactobacilli 
The main metabolites 
of Lactobacillus spp. 
act cooperatively to kill 
BV-associated bacteria 
(Atassi and 
Servin 
2010) 
Lactobacillus 
rhamnosus, 
Lactobacillus 
reuteri and 
Gardnerella 
spp. 
The secreted 
products of L. 
rhamnosus and 
L. reuteri 
infiltrated BV 
biofilms and 
caused bacterial 
cell death 
Possible production 
of acid, bacteriocins 
or biosurfactant-like 
substances by L. 
rhamnosus and L. 
reuteri 
Lactobacilli can induce 
a return to a normal 
microbiota from a BV 
state 
(McMillan et al. 
2011) 
Lactobacillus 
spp. and 
Gardnerella 
spp. 
Lactobacillus 
showed 
antagonistic 
activity against 
Gardnerella 
spp. 
Unknown Success in the BV 
development depends 
on the presence of 
Lactobacillus species 
(Teixeira et al. 
2012) 
Lactobacillus 
crispatus and 
Gardnerella 
spp. 
L. crispatus 
produced lactic 
acid and 
inhibited the 
growth of 
Gardnerella 
spp. on an ex 
vivo porcine 
vaginal mucosal 
model 
Production of 
antimicrobial 
compounds by L. 
crispatus 
A stable L. crispatus 
colonization of live 
vaginal mucosa is able 
to prevent colonization 
of Gardnerella spp. in 
a pH-dependent 
manner 
(Breshears et al. 
2015) 
L. 
acidophilus, 
L. 
rhamnosus, 
Lactobacillus 
were able to 
inhibit the 
growth of both 
The effect could be 
due to the production 
of lactic acid, H2O2,
and bacteriocins 
L. acidophilus alone or 
combined with L. 
rhamnosus can be used 
in probiotic products to 
(Bertuccini et 
al. 2017) 
and 
Gardnerella 
spp. and A. 
vaginae 
Gardnerella 
spp. and A. 
vaginae 
prevent bacterial 
infections 
Table 4. Bacterial interactions occurring between Gardnerella spp. and other STIs-associated 
microbes. 
Microbes Interaction Mechanism Effect in host References 
Gardnerella 
spp., other 
BV-
associated 
bacteria 
and 
Chlamydia 
trachomatis 
Cooperative 
interactions 
between 
Gardnerella 
spp., other BV-
associated 
bacteria, and C. 
trachomatis 
Production of 
sialidase and 
other glycosides 
by Gardnerella 
spp., which can 
potentially alter 
mucosal integrity 
and facilitate 
infection with 
genital pathogens 
Detrimental 
changes to the 
mucosal barrier 
(Wiesenfeld et al. 
2003) 
Gardnerella 
spp. and 
Neisseria 
gonorrhoea
e 
Gardnerella 
spp. and other 
BV-bacteria are 
associated with 
an increase 
acquisition of N. 
gonorrhoeae 
colonization 
Production of 
sialidase and 
other glycosides 
by Gardnerella 
spp., which can 
potentially alter 
mucosal integrity 
and facilitate 
infection with 
genital pathogens 
Detrimental 
changes to the 
mucosal barrier 
(Wiesenfeld et al. 
2003) 
Gardnerella 
spp., other 
vaginal 
pathogens 
and HSV-2 
Common 
bacteria found 
in vaginal 
dysbiosis are 
associated with 
increased 
acquisition of 
HSV 
BV-associated 
bacteria propagate 
viral replication 
and vaginal 
shedding of HSV, 
thereby further 
enhancing spread 
of this STI 
Viral replication 
and vaginal 
shedding of HSV 
(Cherpes et al. 
2005) 
Gardnerella 
spp., other 
vaginal 
pathogens 
and HPV 
Gardnerella, 
other BV-
associated 
bacteria which 
produce mucin-
degrading 
enzymes, and 
HPV 
Mucin-degrading 
enzymes present 
in Gardnerella 
spp. might 
degrade the gel 
layer coating the 
cervical 
epithelium, 
causing micro-
abrasions or 
alterations of 
epithelial cells 
Detrimental 
changes to the 
mucosal barrier 
(Gillet et al. 
2011) 
Gardnerella 
spp. and 
Trichomona
s vaginalis 
Cooperative 
interactions 
between 
Gardnerella 
spp., bacteria 
belonging to 
CST-IV, and T. 
vaginalis 
Gardnerella spp. 
induced higher 
chemokine 
responses (namely 
to 
IL-8 and 
RANTES) and 
amplified the pro-
inflammatory 
responses to both 
Lipophosphoglyc
an/ ceramide-
phosphoinositol-
glycan core 
Inflammatory 
damage 
accompanied by 
recruitment of 
CD4 cells; and 
weakened 
antiviral barrier 
(Fichorova et al. 
2013) 
Gardnerella 
spp. and 
HIV 
Gardnerella 
spp. and other 
common 
bacteria found 
in vaginal 
dysbiosis are 
associated with 
increased 
acquisition of 
HIV 
APCs use Toll-
like receptor-4 
signalling to 
respond to LPS, 
which activates 
nuclear factor 
kappa-light-chain-
enhancer of 
activated B cells 
(NF-κB), 
Genital 
inflammation and 
recruitment of 
lymphocytes by 
chemokine 
production 
(Anahtar et al. 
2016) 
Gardnerella 
spp., other 
vaginal 
pathogens 
and HIV 
Gardnerella 
spp. and other 
common 
bacteria found 
in vaginal 
dysbiosis are 
associated with 
increased 
acquisition of 
HIV 
Mucus and 
cytoskeleton 
alterations, 
increasing lactate 
dehydrogenase 
A/B as markers of 
cell death, 
increasing 
proteolytic 
activity, altered 
antimicrobial 
peptide balance, 
increasing 
proinflammatory 
cytokines, and 
decreasing 
immunoglobulins 
Cervicovaginal 
inflammation and 
other 
detrimental 
changes to the 
mucosal barrier 
(Borgdorff et al. 
2016) 
Gardnerella 
spp. and 
HIV 
Gardnerella 
spp. and other 
anaerobes are 
associated with 
increased 
acquisition of 
HIV 
Higher activation 
of CD4+ HIV 
target cells 
Increase HIV risk 
acquisition by 
inducing mucosal 
HIV target cells 
(Gosmann et al. 
2017) 
Gardnerella 
spp., other 
vaginal 
pathogens, 
HIV and 
HSV-2 
High-diversity 
CSTs, 
Gardnerella 
spp., and P. 
bivia were 
strongly 
associated with 
cervicovaginal 
inflammatory 
cytokines 
Genital 
inflammation is a 
key determinant 
of HIV 
transmission and 
may increase 
HIV-susceptible 
target cells and 
alter epithelial 
integrity 
Genital 
microbiota and 
HSV-2 infection 
may influence 
HIV susceptibility 
through 
independent 
biological 
mechanisms 
(Shannon et al. 
2017) 
Gardnerella 
spp. and 
Chlamydia 
trachomatis 
Gardnerella 
spp. infections 
may act as a 
chlamydial 
reservoir 
contributing to 
the transmission 
of C. 
trachomatis in 
the population 
Incorporation of 
C. trachomatis on 
a Gardnerella 
spp. biofilm 
Typical 
chlamydial 
inclusions 
observed in HeLa 
cells monolayers 
(Filardo et al. 
2019) 
Gardnerella 
spp., other 
CST-IV 
bacteria, 
and 
Trichomona
s vaginalis 
Cooperative 
interactions 
between 
Gardnerella 
spp., bacteria 
belonging to 
CST-IV and T. 
vaginalis 
Enhancement of 
the paracellular 
permeability of 
the cervicovaginal 
epithelium by 
disturbing the 
integrity of the 
tight junction 
complex 
Damage on 
cervicovaginal 
epithelium 
(Hinderfeld et al. 
2019) 
Table 5. Common and proposed alternative or preventive treatment strategies used against vaginal 
infections. 
Treatment Reference 
BACTERIAL VAGINOSIS 
Recommended 
antibiotics 
Metronidazole, Clindamycin, 
Tinidazole 
(Workowski and Bolan 2015) 
Proposed alternative 
approaches 
Povidone iodine (Wewalka et al. 2002) 
Hydrogen peroxide (Cardone et al. 2003) 
Lactocin 160 (Turovskiy et al. 2009) 
Octenidine hydrochloride/ 
phenoxyethanol  
(Novakov Mikic and Budakov 2010) 
Thymol (Braga et al. 2011) 
Silicon-coated tablets containing 
250 mg vitamin C 
(Polatti et al. 2006; Petersen et al. 2011) 
Mixture of thymol and eugenol (Sosto, Benvenuti and CANVA Study Group 2011) 
Nifuratel (Togni et al. 2011) 
Benzydamine hydrochloride (Boselli et al. 2012) 
Glycerol monolaurate (Sutyak Noll et al. 2012) 
Lauramide arginine ethyl ester (Turovskiy et al. 2012) 
Benzoyl peroxide formulated 
polycarbophil/ carbopol 934P 
hydrogel 
(Xu et al. 2013) 
Subtilosin (Cavera, Volski and Chikindas 2015) 
Boric acid (Zeron Mullins and Trouton 2015) 
Thymbra capitata essential oil 
Benzoyl peroxide 
(Machado et al. 2017) 
(Algburi et al. 2018) 
Dequalinium chloride (Sherrard et al. 2018) 
Probiotics (Homayouni et al. 2014; van de Wijgert and 
Verwijs 2019) 
TOL-463 (boric acid-based 
vaginal anti-infective with 
enhanced antibiofilm activity) 
(Marrazzo et al. 2019) 
Cationic amphiphiles (Weeks et al. 2019) 
VULVOVAGINAL 
CANDIDIASIS 
Recommended 
antifungal drugs 
Clotrimazole, Miconazole, 
Tioconazole, Butoconazole, 
Terconazole, Fluconazole 
(Workowski and Bolan 2015) 
Proposed alternative 
approaches 
Povidone iodine (Kondo et al. 2012) 
Garlic pills (Watson et al. 2014) 
Propolis (Grenier Capoci et al. 2015) 
Boric acid (Pointer, Boyer and Schmidt 2015) 
Probiotics (Buggio et al. 2019) 
TOL-463 (boric acid-based 
vaginal anti-infective with 
enhanced antibiofilm activity) 
(Marrazzo et al. 2019) 
TRICHOMONIASIS 
Recommended 
antibiotics 
Metronidazole, Tinidazole (Workowski and Bolan 2015) 
Proposed alternative 
approaches 
Boric acid (Aggarwal and Shier 2008; Backus, Muzny and 
Beauchamps 2017) 
Medicinal plants (Mehriardestani et al. 2017) 
Phytochemicals (Setzer et al. 2017) 
Proposed preventive 
therapy 
Vaccines (Xie et al. 2017) 
CHLAMYDIA 
Recommended 
antibiotics 
Azithromycin, Doxycycline (Workowski and Bolan 2015) 
Proposed preventive 
therapy 
Vaccines (Hafner and Timms 2018) 
GONORRHEA 
Recommended 
antibiotics 
Ceftriaxone, Azithromycin (Workowski and Bolan 2015) 
Proposed preventive 
therapy 
Vaccines (Jerse and Deal 2013; Edwards, Jennings and Seib 
2018) 
VIRAL VAGINITIS 
Proposed preventive 
therapy  
Vaccines (Petrosky et al. 2015; Hsu and O’Connell 2017; Xu, 
Zhang and Li 2019) 
